Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 56 |
| Active Pipeline (Recruiting Now) | 18 (12) |
| Completed vs Stopped Early | 22 / 5 (8.9%) |
| Median Closed Actual Enrollment | 123 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Peking Union Medical College Hospital | Beijing, Beijing Municipality | 6 |
| Chinese PLA General Hospital | Beijing | 5 |
| Shanghai Chest Hospital | Shanghai | 3 |
Explore interactive annual charts and M&A subsidiary rollups in the Suzhou Zelgen Biopharmaceuticals Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.